UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries
|
|
- Lindsey O’Connor’
- 5 years ago
- Views:
Transcription
1 UNIVAC decision support model A universal framework for evaluating vaccine policy options in low- and middle-income countries Andrew Clark, London School of Hygiene and Tropical Medicine
2 Key questions 1. How do you access, navigate and run UNIVAC? 2. How are the UNIVAC inputs used to generate outputs?
3 Key questions 1. How do you access, navigate and run UNIVAC? 2. How are the UNIVAC inputs used to generate outputs?
4 Key questions 1. How do you access, navigate and run UNIVAC? 2. How are the UNIVAC inputs used to generate outputs?
5 Main output (outcome measure) 1. Cost-utility ratio Cost per DALY averted
6 Outputs of UNIVAC 1. Cost-utility ratio Cost per DALY averted 2. Vaccine costs Incremental vaccine costs 3. Healthcare costs Healthcare costs averted 4. Disease events Cases, visits, hosps., deaths, DALYs 5. Adverse events Cases, visits, hosps., deaths, DALYs 6. Benefit-risk ratio e.g. Deaths averted per death caused
7 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages
8 BIRTH COHORTS CALENDAR YEARS
9 BIRTH COHORTS Population, no vaccine CALENDAR YEARS etc... Years of age 9
10 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages Multiply by age-specific rates of disease per 100,000 per year to estimate numbers of disease events
11 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS etc... Years of age 11
12 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Years of age For simplicity, this example focuses on disease in under-fives 12
13 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Years of age 13
14 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages Multiply by age-specific rates of disease per 100,000 per year to estimate numbers of disease events If you want to account for changes in inputs over time (e.g. demography, mortality rates, coverage, price) then repeat for up to 30 birth cohorts
15 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Years of age 15
16 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS
17 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS
18 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS
19 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS
20 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS
21 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Also useful if you want to report results by calendar year
22 Without vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by using United Nations Population Division (UNPOP) projections of the number of individuals that will be alive in each single year of age (and single calendar year) as the birth cohort ages Multiply by age-specific rates of disease per 100,000 per year to estimate numbers of disease events If you want to account for changes in inputs over time (e.g. demography, mortality rates, coverage, price) then repeat for up to 30 birth cohorts Repeat for each disease type and outcome
23 Disease type 1 Cases Visits Hosps. Deaths
24 Cases Visits Hosps. Deaths Disease type 1 Disease type 2
25 Cases Visits Hosps. Deaths Disease type 1 Disease type 2 Disease type 3 up to 10 types
26 Example: Rotavirus configuration 1 Cases Visits Hosps. Deaths Any RVGE
27 Example: Rotavirus configuration 2 Cases Visits Hosps. Deaths Any RVGE
28 Example: Rotavirus configuration 3 Cases Visits Hosps. Deaths Any GE
29 Example: Rotavirus configuration 4 Cases Visits Hosps. Deaths Non-severe RVGE Severe RVGE
30 Example: Rotavirus configuration 5 Cases Visits Hosps. Deaths Non-severe RVGE Severe RVGE Intussusception The background rate of severe adverse events can also be included if required. Users can then enter the relative risk of vaccination compared to this background rate to estimate vaccine-related events.
31 With vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by specifying the period of vaccination
32 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Vaccinate infants born
33 With vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by specifying the period of vaccination Multiply age-specific disease events by: 1 [ (% covered by only 1 dose x efficacy of dose 1) + (% covered by only 2 doses x efficacy of dose 2) + (% covered by only 3 doses x efficacy of dose 3).etc. ]
34 With vaccination, how many disease events can we expect over the lifetime of a birth cohort? Start by specifying the period of vaccination Multiply age-specific disease events by: 1 [ (% covered by only 1 dose x efficacy of dose 1) + (% covered by only 2 doses x efficacy of dose 2) + (% covered by only 3 doses x efficacy of dose 3).etc. ] This calculation is applied by year of age 5-99 years and by week of age <5 years. UNIVAC therefore asks for additional inputs <5yrs: Age distribution of disease by week of age <5yrs; Vaccine coverage/timeliness by week of age <5yrs; Vaccine efficacy by time in weeks since dose given.
35 BIRTH COHORTS Deaths, no vaccine CALENDAR YEARS Vaccinate infants born
36 BIRTH COHORTS Deaths, routine vaccine CALENDAR YEARS Vaccinate infants born
37 BIRTH COHORTS Deaths, routine vaccine CALENDAR YEARS Vaccinate infants born - and track future benefits
38 COMPARATOR deaths without vaccine NEW OPTION 590 deaths with vaccine e.g. ~50000 future deaths prevented if all children born - are tracked over their lifetimes
39 UNIVAC advantages and drawbacks Advantages Accessibility developed in Excel so familiar to most users; Transparency can be easily explained to national teams and decision makers; Simplicity uses a minimal set of inputs and steps; Flexibility can be quickly adapted to evaluate new options in a timely way; Comparability allows for more standardised comparisons between vaccine policy options; Drawback Static unlike dynamic models, UNIVAC does NOT track the number of susceptible, infectious and immune individuals over time, so cannot directly simulate herd (and other indirect) effects. However, in mitigation (!), calibration of dynamic models: can be a lengthy/complex process; may not provide estimates defensible by MoH if based on poor quality data; may not be necessary if plausible whatif scenarios can demonstrate that inclusion of indirect effects would not change the recommendation/decision.
40 If you want to know more about The PAHO/WHO Provac Initiative The Provac Toolkit Partners
Overview of the ProVac Initiative
Overview of the ProVac Initiative Updated Dec. 2017 Goal of the ProVac Initiative Strengthen evidence-based decision making on immunization to sustain and further the public health impact of immunization
More informationPapillomavirus Rapid Interface for Modelling and Economics Tool. User Manual
Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International
More informationVaccine 31S (2013) C19 C29. Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al hom ep age: e/vaccine
Vaccine 31S (2013) C19 C29 Contents lists available at SciVerse ScienceDirect Vaccine jou rn al hom ep age: wwwelseviercom/locat e/vaccine Review TRIVAC decision-support model for evaluating the cost-effectiveness
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More informationCritical immunity thresholds for measles elimination
Critical immunity thresholds for measles elimination Sebastian Funk Centre for the Mathematical Modelling of Infectious Diseases London School of Hygiene & Tropical Medicine 19 October, 2017!"vöå"!(}å!öZ&!
More informationStrengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative
http://www.paho.org/provac Strengthening evidence-based decision making for new vaccine introduction: PAHO s ProVac Initiative Cara Bess Janusz Immunization, PAHO 1 st Regional Dengue Symposium 3-4 November
More informationIMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION
IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION Marc Brisson Full Professor Université Laval, Canada SAGE meeting October 24, 2018 Geneva 1 Questions A. What is the potential
More informationBurden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination
Carlo GIAQUINTO Pediatrics Department University of Padova, Italy Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Preliminary results 7th International Rotavirus
More informationCost-effectiveness of Influenza Vaccine
Cost-effectiveness of Influenza Vaccine Lisa A. Prosser, PhD, MS Associate Professor University of Michigan National Influenza Vaccine Summit May 16, 2012 Acknowledgments Funding for this research project
More informationUsing a mathematical model to evaluate the impact of different PCV schedules:
Using a mathematical model to evaluate the impact of different PCV schedules: Preliminary results from the West Africa epidemiological scenario Alessia Melegaro 1, Albert Jan van Hoek 2, Yoon Choi 2, Nigel
More informationCrucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C
Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationMeasles Strategic Planning Tool: Analysis of MCV strategies in developing countries. Emily Simons 29 January 2009
Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries Emily Simons 29 January 2009 Overview The MSP tool Results by question For Indian states: what is best strategy to accelerate
More information3. Title Vaccination and immunisation data return collected through the COVER
1. Record Type? 2. Unique Number Reassessment R00019 3. Title Vaccination and immunisation data return collected through the COVER 4. Collection Type National 5. Other Reference 6. Description Cover of
More informationMark Jit 1,2 1. Improving health worldwide. London School of Hygiene & Tropical Medicine 2. Modelling and Economics Unit, Public Health England
Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, Geneva, 17-18 April 2018 Full public health value proposition of vaccines (FPHVPs) Global economic investment case for vaccines
More informationUsing A Transmission Dynamic Model Of Rotavirus Infection To Determine The Cost- Effectiveness Of Rotavirus Vaccination In Bangladesh
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2015 Using A Transmission Dynamic Model Of Rotavirus Infection To Determine
More informationSummary of WHO Position on Rotavirus. Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India)
Summary of WHO Position on Rotavirus Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India) Presentation WHO Position Papers on Rotavirus Optimizing immunization
More informationHealth technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:
Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical
More informationRift Valley fever in Kenyan pastoral livestock: Individual-based demographic model to analyse the impact of Rift Valley fever
Rift Valley fever in Kenyan pastoral livestock: Individual-based demographic model to analyse the impact of Rift Valley fever S. Fuhrimann 1,2, T. Kimani 3,4, F. Hansen 3, B. Bett 3, J. Zinsstag 1,2, E.
More informationVaccine 26S (2008) F3 F15. Contents lists available at ScienceDirect. Vaccine. journal homepage:
Vaccine 26S (2008) F3 F15 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Review Evolution of the health economics of cervical cancer vaccination Nicole
More informationIntroduction to the ProVac Initiative
Introduction to the ProVac Initiative E-toolkit training module Nathalie El Omeiri, PAHO/WHO, Washington D.C. Family, Health Promotion and Life Course, Immunization unit, elomeirin@paho.org Contents of
More informatione-bug: Vaccinations Teacher Sheet Student worksheet 1 answers
Student worksheet 1 answers 1. The table below provides the percentage of children immunised by their second birthday against measles, mumps and rubella (MMR) between 1996 and 2014 (England only). This
More informationUSING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa
USING MATHEMATICAL MODELING FOR POLICY AND STRATEGIC PLANNING A case study of VMMC Scale-Up in Eastern and Southern Africa INTEREST 2018 Kigali, Rwanda Emmanuel Njeuhmeli, MD, MPH, MBA Senior Medical Advisor
More informationCost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada
Cost-Effectiveness of Quadrivalent vs Monovalent Vaccination against Meningococcal Disease in Canada Derek Weycker, Ph.D. 1 Mark Atwood, M.S. 1 Thomas E. Delea, M.S.I.A. 1 Anoush Youssoufian, B.A. 1 Dion
More informationGender (in)equality in Human Papilloma Virus (HPV) vaccinations and treatment Prof. Giampiero Favato
Gender (in)equality in Human Papilloma Virus (HPV) vaccinations and treatment Prof. Giampiero Favato Institute of Leadership and Management in Health (ILMH) Kingston University London 1 HPV virus: a gender
More informationReporting and Interpreting Results of Economic Evaluation
Reporting and Interpreting Results of Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationEconomic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M
Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia Pokorn M, Kopac S, Neubauer D, Cizman M Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationChallenges of use of cholera vaccines in Haiti and the Americas
http://www.paho.org Challenges of use of cholera vaccines in Haiti and the Americas Dr. Cuauhtémoc Ruiz Matus Comprehensive Family Immunization Program Background Topics Consultations at PAHO Challenges
More informationModeling the public health impact of malaria vaccines for developers and policymakers
Nunes et al. BMC Infectious Diseases 2013, 13:295 RESEARCH ARTICLE Modeling the public health impact of malaria vaccines for developers and policymakers Julia K Nunes 1,9*, Vicky Cárdenas 1,2, Christian
More informationData inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov
Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov Vaccine & Infectious Disease Division Fred Hutchinson Cancer Research Center Dynamic model integration The
More informationThe cost-effectiveness of vaccination against Lyme disease Shadick N A, Liang M H, Phillips C B, Fossel K, Kuntz K M
The cost-effectiveness of vaccination against Lyme disease Shadick N A, Liang M H, Phillips C B, Fossel K, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationImpact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries
August 29, 2018 Impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries Thirteenth International Rotavirus Symposium 29 31 August 2018 Minsk, Belarus Frédéric Debellut Health Economist,
More informationGSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:
GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)
More informationModelling screening of HPV vaccinated birth cohorts. The infection transmission system
Modelling screening of HPV vaccinated birth cohorts Dr. Iacopo Baussano Imperial College, London & UPO/CPO-Piemonte, Italy. The infection transmission system Infectious Agent in case of CC: men in case
More informationPotential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078
Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078 Kate M Mitchell, Brooke Hoots, Dobromir Dimitrov, Jason Farley,
More informationPutting it together: The potential role of modeling to explore the impact of FMD
Putting it together: The potential role of modeling to explore the impact of FMD Mo Salman Animal Population Health Institute Colorado State University m.d.salman@colostate.edu And Melissa McLaws European
More informationInfectious Disease Surveillance in NZ. Michael Baker Department of Public Health, University of Otago, Wellington
Infectious Disease Surveillance in NZ Michael Baker Department of Public Health, University of Otago, Wellington michael.baker@otago.ac.nz Outline Current best practice High quality surveillance of specific
More informationEconomic Evaluation. Defining the Scope of a Costeffectiveness
Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes
More informationStakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand
Stakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand Date: Location: Thursday 2 nd August 2018, 9am 12pm Health Intervention and Technology Assessment Program
More informationReflections on the use of future HIV vaccines as part of an integrated package of preventive measures
Reflections on the use of future HIV vaccines as part of an integrated package of preventive measures Walter Jaoko, KAVI Institute of Clinical Research, University of Nairobi 2016 Global Vaccine & Immunization
More informationPertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A
Pertussis in adolescents and adults: should we vaccinate Lee G M, LeBaron C, Murphy T V, Lett S, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationReport to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid
Annex B: Background and Overview of Analyses Gavi s Historical Decisions on TCV In the 2008 VIS, the Board prioritised TCVs for Gavi s portfolio along with Rubella, HPV, and JE vaccines. Although no financial
More informationTuberculosis Tutorials
Tuberculosis Tutorials These tuberculosis (TB) tutorials were created for the EMOD QuickStart v1.8. Later versions of the QuickStart may not be completely compatible with these tutorials as installation
More informationSetting The setting was community. The economic study was carried out in the USA.
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children Lieu T A, Ray G T, Black S R, Butler J C, Klein J O, Breiman R F, Miller M A, Shinefield H R Record
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationModelling BCG vaccination in the UK: What is the impact of changing vaccination policy?
Modelling BCG vaccination in the UK: What is the impact of changing vaccination policy? Sam Abbott Supervisors: Hannah Christensen, Ellen Brooks-Pollock University of Bristol 1 1. Lambert, M. L., Hasker,
More informationThe English immunization programme
The English immunization programme Mary Ramsay Head of Immunisation Public Health England National Health Service Constitution (2009) You have the right to receive the vaccinations that the Joint Committee
More informationModelling HIV prevention: strengths and limitations of different modelling approaches
Modelling HIV prevention: strengths and limitations of different modelling approaches Leigh Johnson Centre for Infectious Disease Epidemiology and Research Background Models of HIV differ greatly in their
More informationWHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI
WHO Rotavirus Vaccine Update 2012 Dr. Fatima Serhan WHO/FWC/IVB/EPI WHO estimates that 453 000 child deaths occurred during 2008 due to rotavirus infection 41057 32653 39144 98621 82% of these deaths occurred
More informationSetting The setting was primary care. The economic study was carried out in Norway.
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program Wisloff T, Abrahamsen T G, Bergsaker M A, Lovoll O, Moller P, Pedersen M K, Kristiansen
More informationModelling Innovative Diagnostic Tools for Tuberculosis
Modelling Innovative Tools for Tuberculosis Ivor Langley Basra Doulla, MoH, Tanzania Hsien-Ho Lin, NTU, Taiwan Kerry Millington Bertie Squire HaCRIC11 - SEPTEMBER 2011 Modelling Innovative Tools for Tuberculosis
More informationMalaria Vaccine Implementation Programme Framework for Policy Decision
Malaria Vaccine Implementation Programme Framework for Policy Decision Mary J Hamel, IVR SAGE 17 April 2018 1 Questions for SAGE on the Framework for Policy Decision 1. Does SAGE agree with the approach?
More informationCost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C
Cost-effectiveness of influenza vaccination in high-risk children in Argentina Dayan G H, Nguyen V H, Debbag R, Gomez R, Wood S C Record Status This is a critical abstract of an economic evaluation that
More informationMalaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018
Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision Mary J Hamel, WHO MPAC, 11 April 2018 MVIP update Background to MVIP MVIP Updates Regulatory Vaccine introduction
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationAppendix. Lifetime extrapolation of data from the randomised controlled DiGEM trial
Appendix Lifetime extrapolation of data from the randomised controlled DiGEM trial Judit Simon, Alastair Gray, Philip Clarke, Alisha Wade, Andrew Neil, Andrew Farmer on behalf of the Diabetes Glycaemic
More informationDownloaded from:
Christensen, H; Trotter, CL; Hickman, M; Edmunds, WJ (2014) Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ (Clinical research ed), 349.
More informationEConDA Economics of Chronic Diseases
EConDA Economics of Chronic Diseases www.econdaproject.eu Funding from the European Union in the framework of the Health Programme Abbygail Jaccard Deputy Director of Public Health Modelling UK Health
More informationGavi Alliance Strategy : Goal level indicators and disease dashboard
Gavi Alliance Strategy 2016-2020: Goal level indicators and disease dashboard BOARD MEETING Peter Hansen and Hope Johnson 10-11 June 2015, Geneva Reach every child www.gavi.org Strategic enablers Goal-level
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design
GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination
More informationGavi s Vaccine Investment Strategy
Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment
More informationModelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence
Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence Kate Mitchell, PhD Imperial College London London, UK 14 th June 2016 Introduction: HPTN 078 Enhancing
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationSun-Young Kim 1,2, Steven Sweet 1, Joshua Chang 1 and Sue J Goldie 1,2* Abstract
RESEARCH ARTICLE Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden Sun-Young Kim
More informationEconomic evaluations of non-traditional vaccinations in middle-income countries Suwantika, Auliya Abdurrohim
University of Groningen Economic evaluations of non-traditional vaccinations in middle-income countries Suwantika, Auliya Abdurrohim IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationAssessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model
Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model Aggarwal R, Ghoshal U C, Naik S R Record Status This is
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationSummary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013
Summary of s of Mission and Strategic Goal Level Indicators in GAVI Alliance Strategy 2011-2015 Updated October 2013 Table of Contents Under five mortality rate ------------------------------------------------------------------------------------------------------------------------
More informationCost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar
CPHA 2009 Cost effectiveness analysis of the new pneumococcal conjugate vaccine (Synflorix TM ) compared to Prevnar Ismaila AS 1,2, Pereira JA 1, Robson RC 1, Rawson NS 1, Simpson SD 1, Standaert BA 3
More informationWhat are the outputs? What is generated by whom? Decade of Vaccine Economics (DOVE) 18/07/2014
HEALTH IMPACT ESTIMATES & ECONOMIC ANALYSES ARE CRUCIAL TO GLOBAL EFFORTS Decade of Vaccine Economics (DOVE) Costing, Financing and Funding Gap (CFF) Model Presented to IVIR June 17, 2014 Sachi Ozawa,
More informationBudget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_
Volume 12 Number 6 2009 VALUE IN HEALTH Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedulevhe_534 888..898 Richard J. Milne,
More informationA. Green, C. Sortsø, P.B. Jensen, M. Emneus
A. Green, C. Sortsø, P.B. Jensen, M. Emneus European Diabetes Epidemiology Group EDEG 2015, Chantilly, April 25-27, 2015 The Diabetes Impact Study 2013 uses all available register information on diabetes
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationEvaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM)
Evaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM) ARCC Conference Monday, May 27, 2013 Presented by William Flanagan
More informationJTEG s Summary of RTS,S/ AS01 Clinical Trial Data
JTEG s Summary of RTS,S/ AS01 Clinical Trial Data Peter Smith On behalf of the Joint Technical Expert Group (JTEG) based on Cohen et al 2010 RTS,S/AS01 Malaria Vaccine l Based on large segment of P. falciparum
More informationEconomic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland
Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina
More informationImmunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules
Immunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules Frank DeStefano MD, MPH Immunization Safety Office Division of Healthcare Quality Promotion, National
More informationHealth technology The screening of newborns for galactosemia (GAL) using the Beutler test was studied.
Cost-benefit analysis of newborn screening for galactosemia in the Philippines Padilla C D, Dans L F, Estrada S C, Tamondong M R, Laceste J J, Bernal R M Record Status This is a critical abstract of an
More informationTHE AFIX PRODUCT TRAINING MANUAL
THE AFIX PRODUCT TRAINING MANUAL Last Updated: 11/30/2018 Table of Contents The AFIX Product End User Training AFIX Cohort. 4 Provider Selection... 4 Assessment Selection..... 7 Reports.......10 Flexible
More informationDecision Analysis. John M. Inadomi. Decision trees. Background. Key points Decision analysis is used to compare competing
5 Decision Analysis John M. Inadomi Key points Decision analysis is used to compare competing strategies of management under conditions of uncertainty. Various methods may be employed to construct a decision
More informationExperience with maternal pertussis and PCV13 immunisation in England
Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November
More informationGlobal reductions in measles mortality and the risk of measles resurgence
Global reductions in measles mortality 2000 2008 and the risk of measles resurgence Measles is one of the most contagious human diseases. In 1980 before the use of measles vaccine was widespread, there
More information6IATT Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+
Costing Tool: Considerations in Costing a Transition to Option B/B+ 6IATT Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+ www.emtct-iatt.org
More informationCost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Hornberger J, Robertus K Record Status This is a critical abstract of an economic evaluation that meets
More informationSchedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE
1 Schedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE Andrew Pollard, SAGE Member SAGE meeting, 18 20 October 2016 Questions for SAGE 2 1. What is the incremental
More informationCost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J
Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J Record Status This is a critical abstract of an economic evaluation
More informationRotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development
More informationEconomic aspects of viral hepatitis in Turkey. Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009
Economic aspects of viral hepatitis in Turkey Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009 Vaccines currently recommended for children in National Immunization
More informationCost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A
Cost effectiveness of pertussis vaccination in adults Lee G M, Murphy T V, Lett S, Cortese M M, Kretsinger K, Schauer S, Lieu T A Record Status This is a critical abstract of an economic evaluation that
More informationGisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services
Gisele Almeida Public Policies, Regulation, and Health Financing Health Systems and Services Challenges to the Health Sector External Context Complexity of health determinants Multiplicity of initiatives
More informationConcepts of herd immunity and protection
Fondation Mérieux Conference Herd Immunity/Protection: an Important Indirect Benefit of Vaccination - Annecy- 26 th October 2010 Concepts of herd immunity and protection Peter Smith London School of Hygiene
More informationDoes your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research
Does your family planning program need a Reality Check? Leah Jarvis, MPH Program Associate for Monitoring, Evaluation, and Research Objectives By the end of the session, participants will be able to: Recognize
More informationModelling of Infectious Diseases for Prevention and Mitigation: How Modelling has Informed Public Health Policy
Modelling of Infectious Diseases for Prevention and Mitigation: How Modelling has Informed Public Health Policy Ruth Chapman, PhD UBC Kamal Desai PhD UBC Deirdre Hollingsworth, PhD Imperial College London
More informationMale Circumcision: Decision Makers Program Planning Tool
Suggested citation: Bollinger, L., W. DeCormier Plosky, and J. Stover. 2009. Male Circumcision: Decision Makers Program Planning Tool, Calculating the Costs and Impacts of a Male Circumcision Program.
More informationAssessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination
Assessing the Evidence for Potential Benefits and Risks of Removing the Age Restrictions for Rotavirus Vaccination Manish Patel SAGE Geneva 12 April 2012 1 Overview! Update new inputs for benefit risk
More information